Benzinga | Oct 6, 2020 07:03AM EDT

Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy

AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months

* 21-point mean improvement in UPDRS Part III "OFF" score, a 40% improvement from baseline, exceeding pre-defined criteria for success

* Greater than 2-hour improvement from baseline in both diary "good ON time" and diary OFF time assessments

* EXPLORE-PD, a randomized, sham-controlled study of AXO-Lenti-PD is expected to begin dosing in 2021